Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis (Q33983611)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis (English)

1 reference

Europe PubMed Central

30 July 2017

cystic fibrosis

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Montgomery MJ

1

1 reference

Europe PubMed Central

30 July 2017

Beringer PM

2

1 reference

Europe PubMed Central

30 July 2017

Aminimanizani A

3

1 reference

Europe PubMed Central

30 July 2017

Louie SG

4

1 reference

Europe PubMed Central

30 July 2017

Shapiro BJ

5

1 reference

Europe PubMed Central

30 July 2017

Jelliffe R

6

1 reference

Europe PubMed Central

30 July 2017

Gill MA

7

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

1 December 2001

1 reference

Europe PubMed Central

30 July 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

30 July 2017

45

1 reference

Europe PubMed Central

30 July 2017

12

1 reference

Europe PubMed Central

30 July 2017

3468-3473

1 reference

Europe PubMed Central

30 July 2017

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Management of pulmonary disease in patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Pharmacokinetics of ciprofloxacin in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

5 July 2018

Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90855

29 October 2018

Liquid-chromatographic determination of ciprofloxacin in serum and urine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11709326

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11709326

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11709326

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/11709326

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.45.12.3468-3473.2001

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33983611&oldid=1962213651"